Table 3 Multivariate analysis of factors associated with DFS and OS

Menstrual status (Post - vs. Pre/Peri-)

/

/

2.33 (1.69–3.22)

<  0.001

Neo-adjuvant therapy (Yes vs. No)

2.51 (1.91–3.30)

<  0.001

2.39 (1.61–3.56)

<  0.001

Breast surgery (BCS vs. Mastectomy)

1.00 (0.77–1.30)

0.992

0.73 (0.47–1.12)

0.149

Tumor size (>  2.0 cm vs. ≤ 2.0 cm)

1.54 (1.26–1.88)

<  0.001

1.81 (1.32–2.48)

<  0.001

ALN status (Positive vs. Negative)

1.58 (1.29–1.93)

<  0.001

2.15 (1.57–2.93)

<  0.001

Histological grade

<  0.001

<  0.001

III vs. I/II

1.44 (1.15–1.81)

1.69 (1.19–2.40)

NA vs. I/II

1.58 (1.21–2.06)

2.02 (1.36–3.01)

LVI (Yes vs. No)

1.26 (0.90–1.75)

0.176

1.55 (0.94–2.54)

0.084

ER

0.074

<  0.001

10–49% vs. 1–9%

1.18 (0.72–1.94)

0.95 (0.52–1.73)

≥ 50% vs. 1–9%

0.89 (0.55–1.45)

0.44 (0.24–0.78)

PR (≥ 20% vs. <  20%)

0.82 (0.67–1.00)

0.050

0.77 (0.55–1.07)

0.118

Ki-67 (≥ 14% vs. <  14%)

1.49 (1.21–1.85)

<  0.001

1.43 (1.02–2.00)

0.037

Radiotherapy (Yes vs. No)

0.97 (0.78–1.21)

0.790

1.09 (0.74–1.59)

0.675

Chemotherapy (Yes vs. No)

1.15 (0.91–1.46)

0.236

0.94 (0.66–1.35)

0.744

Endocrine therapy (Yes vs. No)

0.56 (0.41–0.76)

<  0.001

0.46 (0.30–0.71)

<  0.001

Group (HER2-pos-T vs. HER2-neg)

0.52 (0.37–0.73)

<  0.001

0.38 (0.22–0.67)

0.037